Mira Pharmaceuticals Inc
MIRA
Company Profile
Business description
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.
Contact
1200 Brickell Avenue
Suite 1950 No. 1183
MiamiFL33133
USAT: +1 786 432-9792
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
2
Stocks News & Analysis
stocks
Are ASX REITs the better way to own property?
Cheap valuations, strong yields and a changing Aussie property landscape.
stocks
Cheap Dividend Aristocrat has Fair Value raised after earnings
Dividend forecasts raised after balance sheet regains strength.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,279.00 | 3.00 | -0.03% |
| CAC 40 | 8,597.04 | 39.75 | -0.46% |
| DAX 40 | 26,395.71 | 44.60 | -0.17% |
| Dow JONES (US) | 53,732.41 | 107.58 | -0.20% |
| FTSE 100 | 10,739.03 | 11.08 | -0.10% |
| HKSE | 25,453.23 | 336.38 | 1.34% |
| NASDAQ | 26,729.16 | 73.86 | -0.28% |
| Nikkei 225 | 69,220.25 | 506.45 | 0.74% |
| NZX 50 Index | 13,721.98 | 132.40 | -0.96% |
| S&P 500 | 7,785.76 | 0.00 | 0.00% |
| S&P/ASX 200 | 9,073.20 | 6.10 | -0.07% |
| SSE Composite Index | 3,982.65 | 55.48 | 1.41% |